Get the Stockscreener App
0.2776
5.58%
-0.0164
Pre-market:
.28
0.0024
+0.86%
Theriva Biologics Inc stock is traded at $0.2776, with a volume of 1.71M.
It is down -5.58% in the last 24 hours and down -4.60% over the past month.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11. It has collaborations with The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
See More
Previous Close:
$0.294
Open:
$0.281
24h Volume:
1.71M
Relative Volume:
0.07
Market Cap:
$12.74M
Revenue:
-
Net Income/Loss:
$-21.46M
P/E Ratio:
-0.1096
EPS:
-2.5324
Net Cash Flow:
$-14.40M
1W Performance:
+14.85%
1M Performance:
-4.60%
6M Performance:
+34.24%
1Y Performance:
-40.57%
1-Day Range:
$0.2703
$0.29
1-Week Range:
$0.2374
$0.446
52-Week Range:
$0.1628
$0.8632
Theriva Biologics Inc Stock (TOVX) Company Profile
Name
Theriva Biologics Inc
Sector
Industry
Phone
301 417 4364
Address
9605 Medical Center Drive, Suite 270, Rockville
Compare TOVX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TOVX
Theriva Biologics Inc
|
0.2776 | 13.49M | 0 | -21.46M | -14.40M | -2.5324 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Theriva Biologics Inc Stock (TOVX) Latest News
TOVX Should I Buy - Intellectia AI
Why is Theriva stock gaining Monday? - MSN
Theriva Biologics (TOVX) Surges Over 26%: Key Levels to Watch After BreakoutCall Resistance - newsline.com
Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention - TechStock²
Theriva Biologics reports survival data from VCN-01 cancer trial - Investing.com
Theriva Biologics highlights promising VCN-01 Phase 1 results - TipRanks
$Theriva Biologics (TOVX.US)$ - Moomoo
Theriva Biologics (NYSE American: TOVX) shares VCN-01 Phase 1 head and neck cancer data - Stock Titan
Small trial: virus-immunotherapy combo linked to longer survival in head and neck cancer - Stock Titan
TOVX Q1 2026 Earnings: Narrower-Than-Expected Loss as Clinical Pipeline AdvancesOperating Margin Analysis - newsline.com
Theriva Biologics Faces Quorum Issue Delaying Warrant Vote - TipRanks
Theriva Biologics (NYSE: TOVX) fails quorum, delays 16.18M-warrant share vote - Stock Titan
MSN Money - MSN
Number of shareholders of Theriva Biologics, Inc. – AMEX:TOVX - TradingView
Theriva Biologics (TOVX) Slides 8% as Stock Tests Key Support at $0.27Dark Pool Sentiment - The Legal Advocate
Theriva Biologics (TOVX) Faces Pressure: Stock Slides 8% as Key Support Levels Are TestedLeveraged ETF Flow - The Legal Advocate
Theriva Biologics (TOVX) Slides 6.15% as Stock Approaches Key Support at $0.28Thematic ETF Flow - newsline.com
Theriva Biologics (TOVX) Advances 4.99% as Stock Approaches Key Resistance at $0.33McClellan Oscillator - newsline.com
Theriva Biologics (TOVX) Gains Nearly 5% as Stock Attempts to Recover Key Support LevelsAI Trade Signals - The Legal Advocate
Theriva Biologics (TOVX) Slides 5.73% as Price Nears Critical Support at $0.28BPI Reversal - The Legal Advocate
Theriva Biologics (TOVX) Q1 2026 Earnings: Slight EPS Beat Boosts Sentiment for Clinical-Stage BiotechMargin Guidance - The Legal Advocate
Theriva Biologics (TOVX) Q1 2026 Earnings: Narrowed Loss Beats Expectations as Stock RisesBanking Earnings Report - Newser
Theriva Biologics (TOVX) Dips 1% as Stock Hovers Near Key Support at $0.28Value Area Low - Newser
Theriva Biologics (TOVX) Hovers Near Support After Modest DeclineCommunity Breakout Alerts - Newser
Theriva Biologics (TOVX) Delivers Q1 2026 Beat — EPS $-0.05 vs $-0.05 ExpectedShared Trade Ideas - Newser
Theriva Biologics (TOVX) Declines -9.35% Amid Market Weakness 2026-05-17Top Analyst Buy Signals - Newser
Theriva Biologics (TOVX) Falls -11.84% — Watching $0.27 Support 2026-05-15Diversification - Newser
BIOLASE Inc (BIOL) - Minichart
TradingKey - TradingKey
TOVX SEC FilingsTHERIVA BIOLOGICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Maxim Group Maintains Theriva Biologics(TOVX.US) With Buy Rating, Maintains Target Price $1 - Moomoo
Theriva Biologics, Inc. Q1 2026 10-Q Report: Financial Statements, Results, and Key Disclosures - Minichart
Theriva Biologics Reports FDA Alignment on VCN-01 Phase 3 Trial Design for Metastatic Pancreatic Cancer and Q1 2026 Financial Results - Minichart
Theriva Biologics, Inc. 1Q 2026: Revenue $300K, Net income ($2.04M), EPS ($0.05) — 10-Q Summary - TradingView
Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results - The Manila Times
Theriva Biologics: Q1 Earnings Snapshot - marketscreener.com
Theriva Biologics (NYSE American: TOVX) posts Q1 loss, flags going concern risk - Stock Titan
Theriva Biologics (NYSE: TOVX) narrows Q1 loss and advances VCN-01 toward pivotal trials - Stock Titan
Theriva moves pancreatic cancer drug toward Phase 3, cash into 2027 - Stock Titan
TOVX Forecast, Price Target & Analyst Ratings | THERIVA BIOLOGICS INC (NYSEARCA:TOVX) - ChartMill
Warrant vote could unlock $8.7M for Theriva Biologics (TOVX) - Stock Titan
TOVX|Theriva Biologics Inc|Price:0.330|Chg%:-0.03 - TradingKey
Theriva Biologics (TOVX) price target decreased by 42.86% to 4.08 - MSN
Trending Stocks Today | Psyence Biomedical Soars 130.26% Pre-Market - Moomoo
Theriva Biologics Inc Stock (TOVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
1.43%
Cap:
|
Volume (24h):